Welcome to our dedicated page for Forwardly news (Ticker: FORW), a resource for investors and traders seeking the latest updates and insights on Forwardly stock.
Forwardly, Inc. (FORW) is an OTC-traded company in the finance and insurance sector whose news flow centers on shareholder updates, investment activities, legal developments, and progress at its partially owned subsidiary and partner, Ligand Innovation Global, Inc. Investors following FORW news can review detailed company statements about its participation in medical device development and its exposure to blockchain-related assets and other ventures.
Many Forwardly news releases focus on the LifeAir G1 Emergency Portable Ventilator, also known as the VitaCaeli Portable Ventilator, which is being developed by Ligand Innovation Global. Updates have covered milestones such as prototype completion, external testing arrangements, patent cooperation treaty designations, regulatory submissions to the United States Food and Drug Administration, and efforts to pursue approvals in jurisdictions such as Nigeria and Ghana. Forwardly’s news also highlights its own role in financing aspects of this project and its commentary on the speculative nature of potential regulatory outcomes and orders.
Other FORW news items describe capital allocation decisions, including the purchase of BLOCKS tokens from Blocks DAO, LLC, warrant exercises and financing related to HUMBL, Inc., and a warrant arrangement with Worldwide NFT, Inc. News releases also document legal actions involving loans to Maverick Energy Group, Inc. and disputes over stock issuances, as well as updates on the resolution or status of those matters.
Because Forwardly often communicates directly with shareholders through formal news releases, the FORW news page provides a centralized view of how the company presents its strategy, partnerships, regulatory interactions, and risk disclosures over time. Readers can use this page to monitor new announcements and review the history of previously reported developments.
Forwardly Inc (OTCMKT: FORW) has provided key updates to shareholders. The company has withdrawn its S-1 filing under the 1934 Act following SEC objections, which requested filing under the 1940 Act. The decision was made due to the additional workload and expenses associated with the 1940 Act filing requirements.
The company's partner, Ligand Innovation Global, reports that their VitaCaeli G1 portable ventilator is approaching FDA approval in Nigeria and Ghana. Potential large orders of thousands of units are expected following approval, possibly during Q2 2025. However, Forwardly emphasizes these developments remain speculative and may not materialize.
Summary not available.
Forwardly, Inc. (OTCMKT: FORW) announced the dismissal of a legal complaint against Emerging Elements, Inc. concerning stock issuance. An agreement was reached after both parties resolved their differences. In addition, the company noted a recent rise in its stock price and trading volume. Forwardly is in initial discussions for a potential acquisition, although details remain speculative. There are assurances that no related parties made advance stock purchases. The company is led by George Sharp, an advocate for shareholder rights and a whistleblower against microcap fraud.
Forwardly, Inc. (OTCMKT: FORW) CEO George Sharp reported significant updates for shareholders. Ligand Innovation Global’s application for Emergency Use Authorization of the LifeAir Portable Ventilator was rejected by the FDA due to a decrease in perceived emergency status. Ligand plans to pursue full FDA approval and seeks international opportunities. Meanwhile, Forwardly's $200,000 convertible loan to Maverick Energy Group is in default, prompting litigation to recover funds. Additionally, Forwardly has invested $200,000 in Worldwide NFT, Inc., acquiring a warrant to buy shares in the future.
Forwardly, Inc. (OTCMKT: FORW) announced that its subsidiary, Ligand Innovation Global, has submitted an application to the FDA for Emergency Use Authorization of the LifeAir Portable Ventilator. This application marks over a year of dedication from the partnership, with a focus on providing cost-effective ventilators to the market. Ligand's CEO emphasized the commitment to innovation, while Forwardly's CEO highlighted the financial backing that made this venture possible. The FDA's decision on the application is awaited.
Forwardly, Inc. (OTCMKT: FORW) announced the acquisition of $250,000 in BLOCKS tokens from Blocks DAO, LLC, utilizing available cash. President George Sharp emphasized the company's belief in blockchain's potential and plans for long-term investment in this asset, alongside exploration of further blockchain opportunities. BLOCKS is positioned as an advanced tokenization standard on the Ethereum network, enabling various applications including payments and real estate.
Forwardly, Inc. (OTCMKT: FORW) successfully demonstrated the LifeAir G1 Portable Ventilator at The Beverly Hills Lung and Sleep Institute, receiving positive feedback from doctors. The event allowed key personnel, including President George Sharp and Dr. Michael Soffer, to assess the product's operation. Ligand Innovation Global, Inc.'s CEO, Dr. Dayo Olakulehin, expressed cautious optimism for FDA submission by Christmas. The ventilator aims to provide low-cost alternatives for developing nations and is expected to significantly reduce emergency equipment costs.
Forwardly, Inc. (OTCMKT: FORW) announced a $2 million debt financing arrangement with CEO George Sharp at 8% APR for 12 months. The funds will be used to purchase 10 million shares of HUMBL, Inc. (OTCMKT: HMBL) through a warrant exercise at $0.20 per share. Forwardly cannot sell these shares until registered with the SEC and aims to avoid selling at depreciated values. This move aligns with Forwardly's strategy as an opportunity investor in the blockchain sector.
Forwardly, Inc. (OTCMKT: FORW) announced that its partner, Ligand Innovation Global, has built two units of the LifeAir G1 Portable Ventilator, with plans for four more prototypes in two weeks. TUV SUD will conduct external testing in October. Ligand is preparing to produce 1,000 units in 2022, addressing global supply chain issues and microchip shortages. The LifeAir G1 aims to provide affordable emergency ventilation solutions for hospitals and nursing homes.
Forwardly, Inc. (OTCMKT: FORW) partner Ligand Innovation Global has received crucial designations for its LifeAir G1 Portable Ventilator under the Patent Cooperation Treaty (PCT). The International Preliminary Examining Authority confirmed the device's novelty, inventiveness, and industrial applicability. This advancement positions the ventilator as an economical solution for hospitals during emergencies. Ligand aims to provide affordable units to medical facilities, enhancing response to respiratory crises.